Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

👴 Amgen announces the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.

🔬 Reese joined Amgen in 2005 and previously served as Executive Vice President of Research and Development from 2018 to 2023.

💡 During his tenure, Reese led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.

🤖 As inaugural Chief Technology Officer, Reese championed the early adoption of technology and artificial intelligence across Amgen's business operations.

🤝 CEO Robert A. Bradway praised Reese for recognizing the impact of biology-technology convergence and positioning Amgen for future patient care.

🚀 Effective June 1, 2026, James Bradner will become Executive Vice President of Research and Development, Artificial Intelligence and Data.

📊 Sean Bruich is set to serve as Senior Vice President, Chief Technology Officer, leveraging his expertise in global insights and AI organizations.

🏛️ Murdo Gordon will take on the role of Executive Vice President for Amgen Global Markets and Policy, including Medical and Commercial Operations.

🩺 Paul Burton will continue serving as Senior Vice President and Chief Medical Officer to reach clinicians with medicines in unmet need areas.

🧬 The organizational changes are designed to deepen the integration of science and technology across Amgen's ecosystem.

💼 Amgen continues to focus on a broad pipeline treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

🏆 The company is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.

📈 Amgen remains part of the Dow Jones Industrial Average and the Nasdaq-100 Index based on market capitalization.

🌐 This press release includes standard forward-looking statements regarding collaborations, financial metrics, and regulatory outcomes.

Bullish Signals
  • The retirement of David M. Reese marks a strategic transition that emphasizes the integration of biology and technology at Amgen.
  • Robert A. Bradway noted that capabilities built under Reese's tenure position the company to advance 'convergent innovation' and better serve patients in the years ahead.
  • James Bradner is stepping into the new role of Executive Vice President, Research and Development, Artificial Intelligence and Data, bringing expertise at the intersection of biology and technology.
  • Sean Bruich will continue as Senior Vice President, Chief Technology Officer, building on a career leading global insights and AI organizations through pivotal moments of industry transformation.
  • Paul Burton, M.D., Ph.D., will remain Senior Vice President, Chief Medical Officer, championing medical breakthroughs in areas of unmet need from cardiovascular to rare diseases.
  • Amgen continues to advance a broad pipeline of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity-related conditions.
  • Amgen has been consistently recognized for innovation and workplace culture with honors from Fast Company and Forbes.
  • As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen remains at the cutting edge of innovation using technology and human genetic data.
Risk Factors
  • The retirement of David M. Reese as Executive Vice President and Chief Technology Officer effective June 30, 2026, signals a significant departure of leadership who had been pivotal in driving the early adoption of technology and artificial intelligence across the business.
  • This organizational change may introduce transition risks to Amgen's 'convergent innovation' strategy as new leaders assume responsibility for critical R&D and AI functions with limited time to implement immediate changes before June 1, 2026.
  • The announcement does not detail specific performance metrics or reasons for Reese's departure other than retirement, leaving uncertainty about the long-term continuity of the technological capabilities he built over his tenure since 2005.
Full Analysis
Amgen has announced the retirement of David M. Reese, who served as Executive Vice President and Chief Technology Officer, effective June 30, 2026. Dr. Reese joined the company in 2005 as a clinical development leader in oncology and previously led Research and Development from 2018 to 2023. During his tenure, he oversaw approvals for numerous innovative medicines and biosimilars while advancing the research pipeline. Notably, as the inaugural CTO, Reese championed the early adoption of technology and artificial intelligence across the business, particularly within R&D operations. His departure is framed as part of a strategic evolution to deepen the integration of biology and technology, supporting the company's "convergent innovation" strategy that combines these fields to accelerate medicine discovery and patient engagement. To facilitate this transition and maintain organizational momentum, Amgen outlined several executive appointments effective June 1, 2026. James Bradner, M.D., a physician-scientist with expertise in emerging technologies, will serve as Executive Vice President of Research and Development, Artificial Intelligence and Data, leveraging his experience to advance biomedical research with new tools. Sean Bruich will assume the role of Senior Vice President and Chief Technology Officer, building on his career leading global insights and AI organizations during industry transformation periods. Additionally, Murdo Gordon has been named Executive Vice President of Amgen Global Markets and Policy, a role encompassing medical, commercial operations, government affairs, and policy, drawing on his track record of strengthening health system partnerships. The company also retained Dr. Paul Burton as Senior Vice President and Chief Medical Officer to continue focusing on reaching clinicians and patients with medicines for unmet needs in areas ranging from cardiovascular disease to rare diseases. CEO Robert A. Bradway stated that the capabilities built during Reese's tenure position Amgen to strengthen its ability to serve patients globally through convergent innovation. This restructuring aims to better connect biology, data science, and advanced technologies throughout the company's operations, supporting Amgen's mission to treat diseases such as cancer, inflammatory conditions, obesity-related conditions, and heart disease while maintaining its reputation for innovation and workplace culture.